Results 161 to 170 of about 3,090 (189)

First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile [PDF]

Investigational New Drugs, 2017
Background Molecular chaperone targeting has shown promise as a therapeutic approach in human cancers of various histologies and genetic backgrounds. The purine-scaffold inhibitor PU-H71 (NSC 750424), selective for Hsp90 in epichaperome networks, has demonstrated antitumor activity in multiple preclinical cancer models. The present study was a first in-
Giovanna Speranza, Larry Anderson, Michelle Eugeni   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Using ¹²⁴I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.

Journal of Clinical Oncology, 2013
11076 Background: PU-H71 is a Heat Shock Protein 90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU-H71) region of interest analysis and dilution principle. A microdose pilot study has shown uptake of *PU-H71 in a variety of tumors.
John F. Gerecitano, Shanu Modi, Devika Gajria, Tony Taldone, Mary Alpaugh, Erica Gomes DaGama, Mohammad Uddin, Gabriela Chiosis, Jason Stuart Lewis, Steven M. Larson, Naga Vara Kishore Pillarsetty, Komal L. Jhaveri, Brian Krichevsky, Mei Hsuan Chen, Payal Dixit, Mark Dunphy   +15 more
openaire   +1 more source

PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α

Molecular and Cellular Biochemistry, 2013
This study is to determine if PU-H71, a heat shock protein inhibitor, induces killing of malignant breast cells together with treatment of tumor necrosis factor-α (TNF-α). The related molecular mechanisms were also studied. A primary mammary epithelial cell line HMEC2595 cells and the highly metastatic breast cell line MDA-MB-231, the HER2-positive BT ...
Zhuling, Qu, Shiduan, Wang, Ruyang, Teng, Xuanlong, Yi   +3 more
exaly   +3 more sources

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2009
Triple-negative breast cancers (TNBCs) are defined by a lack of expression of estrogen, progesterone, and HER2 receptors. Because of the absence of identified targets and targeted therapies, and due to a heterogeneous molecular presentation, treatment guidelines for patients with TNBC include only conventional chemotherapy. Such treatment,
Eloisi Caldas-Lopes, Leandro Cerchietti, Cristina C Clement   +2 more
exaly   +3 more sources

Phase I trial of the HSP-90 inhibitor PU-H71.

Journal of Clinical Oncology, 2015
2537 Background: PU-H71 (PU) is an HSP-90 inhibitor that can be labeled with 124I without altering its biochemical properties. Intratumoral drug concentration can be calculated based on 124I-PU-H71 (*PU) PET imaging, leading to a surrogate marker of intratumoral pharmacokinetics.
John F. Gerecitano, Shanu Modi, Raajit Rampal, Alexander E. Drilon, Matthew G. Fury, Mrinal M. Gounder, James J. Harding, David Michael Hyman, Anna M. Varghese, Martin Henner Voss, Fallon Olga France, Tony Taldone, Erica Gomes DaGama, Mohammad Uddin, Gabriela Chiosis, Jason Stuart Lewis, Serge K. Lyashchenko, Steven M. Larson, Christina Pressl, Mark Dunphy   +19 more
openaire   +1 more source

HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor—PU-H71 (NSC 750424) [PDF]

Journal of Pharmaceutical and Biomedical Analysis, 2014
An HPLC method for the assay of the heat shock protein 90 inhibitor, PU-H71 (NSC 750424), has been developed and validated. The stress testing of PU-H71 was carried out in accordance with ICH guidelines Q1A (R2) under aqueous, acidic, alkaline, oxidative, thermolytic and photolytic conditions.
Mingtao, Liu, Jennie, Wang, Xiaogang, Wu, Euphemia, Wang, Diego, Baptista, Brendan, Scott, Paul, Liu   +6 more
exaly   +3 more sources

MPEC 2023-H71 : 2019 QT

2023
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire   +1 more source

Characterization of Bacillus thuringiensis ser. jordanica (Serotype H71), a Novel Serovariety Isolated in Jordan

Current Microbiology, 2003
The novel strain of Bacillus thuringiensis J112 isolated from a soil sample in Jordan was classified and characterized in terms of toxicity against dipteran and nematode larvae, crystal protein pattern, plasmid profile, and cry gene content. A new name, Bacillus thuringiensis serovariety jordanica (H serotype 71), is proposed for the reference strain ...
Hala, Khyami-Horani, Myriam, Hajaij, Jean-François, Charles   +2 more
openaire   +2 more sources

HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators

Naunyn-Schmiedeberg's Archives of Pharmacology, 2019
Heat shock protein 90 (HSP90) inhibitors are considered as new radiosensitizing agents. PU-H71, a novel HSP90 inhibitor, is under evaluation for the treatment of advanced cancer. It is however not known whether PU-H71 alters radiosensitivity of metastatic breast cancer.
Nuray Erin, Erin Nuray
exaly   +3 more sources